1. Home
  2. AKRO vs RNST Comparison

AKRO vs RNST Comparison

Compare AKRO & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • RNST
  • Stock Information
  • Founded
  • AKRO 2017
  • RNST 1904
  • Country
  • AKRO United States
  • RNST United States
  • Employees
  • AKRO N/A
  • RNST N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • RNST Major Banks
  • Sector
  • AKRO Health Care
  • RNST Finance
  • Exchange
  • AKRO Nasdaq
  • RNST Nasdaq
  • Market Cap
  • AKRO 2.0B
  • RNST 1.8B
  • IPO Year
  • AKRO 2019
  • RNST N/A
  • Fundamental
  • Price
  • AKRO $28.08
  • RNST $35.38
  • Analyst Decision
  • AKRO Strong Buy
  • RNST Buy
  • Analyst Count
  • AKRO 8
  • RNST 5
  • Target Price
  • AKRO $46.83
  • RNST $40.75
  • AVG Volume (30 Days)
  • AKRO 594.3K
  • RNST 556.1K
  • Earning Date
  • AKRO 02-27-2025
  • RNST 01-21-2025
  • Dividend Yield
  • AKRO N/A
  • RNST 2.47%
  • EPS Growth
  • AKRO N/A
  • RNST 6.89
  • EPS
  • AKRO N/A
  • RNST 3.09
  • Revenue
  • AKRO N/A
  • RNST $685,874,000.00
  • Revenue This Year
  • AKRO N/A
  • RNST N/A
  • Revenue Next Year
  • AKRO N/A
  • RNST $36.82
  • P/E Ratio
  • AKRO N/A
  • RNST $11.57
  • Revenue Growth
  • AKRO N/A
  • RNST 8.24
  • 52 Week Low
  • AKRO $15.32
  • RNST $27.98
  • 52 Week High
  • AKRO $37.00
  • RNST $39.47
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 41.87
  • RNST 43.52
  • Support Level
  • AKRO $27.45
  • RNST $34.03
  • Resistance Level
  • AKRO $28.76
  • RNST $36.39
  • Average True Range (ATR)
  • AKRO 1.49
  • RNST 1.03
  • MACD
  • AKRO -0.12
  • RNST -0.11
  • Stochastic Oscillator
  • AKRO 17.98
  • RNST 36.59

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: community banks, insurance, and wealth management. With its community banks segment, the company provides a range of financial services to individuals and small businesses. Its insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The wealth management segment provides a range of services including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment. Renasant Corporation operates in the southern United States.

Share on Social Networks: